Neuronal exosomes reveal Alzheimer's disease biomarkers in Down syndrome

Introduction: Individuals with Down syndrome (DS) exhibit Alzheimer's disease (AD) neuropathology and dementia early in life. Blood biomarkers of AD neuropathology would be valuable, as non-AD intellectual disabilities of DS and AD dementia overlap clinically. We hypothesized that elevations of...

Descripción completa

Detalles Bibliográficos
Autores: Hamlett, ED, Goetzl, EJ, Ledreux, A, Vasilevko, V, Boger, HA, LaRosa, A, Clark, D, Carroll, SL, Carmona-Iragui, M, Fortea, J, Mufson, EJ, Sabbagh, M, Mohammed, AH, Hartley, D, Doran, E, Lott, IT, Granholm, AC
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2017
País:España
Institución:Institut d’Investigació Biomèdica Sant Pau (IIB Sant Pau)
Repositorio:r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
OAI Identifier:oai:iibsantpau.fundanetsuite.com:p6474
Acceso en línea:https://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=6474
https://europepmc.org/articles/pmc5812672
Access Level:acceso abierto
Palabra clave:Intellectual disability
Down syndrome
Alzheimer's disease
Blood biomarkers
Neuronal exosomes
Hyperphosphorylated tau
Amyloid-beta
Descripción
Sumario:Introduction: Individuals with Down syndrome (DS) exhibit Alzheimer's disease (AD) neuropathology and dementia early in life. Blood biomarkers of AD neuropathology would be valuable, as non-AD intellectual disabilities of DS and AD dementia overlap clinically. We hypothesized that elevations of amyloid beta (A beta) peptides and phosphorylated-tau in neuronal exosomes may document preclinical AD. Methods: AD neuropathogenic proteins A beta(1-42), P-T181-tau, and P-S396-tau were quantified by enzyme-linked immunosorbent assays in extracts of neuronal exosomes purified from blood of individuals with DS and age-matched controls. Results: Neuronal exosome levels of A beta(1-42), P-T181-tau, and P-S396-tau were significantly elevated in individuals with DS compared with age-matched controls at all ages beginning in childhood. No significant gender differences were observed. Discussion: These early increases in A beta(1-42), P-T181-tau, and P-S396-tau in individuals with DS may provide a basis for early intervention as targeted treatments become available. (C) 2016 Published by Elsevier Inc. on behalf of the Alzheimer's Association.

Similares en LA Referencia